What is Clearside Biomedical, Inc. (CLSD) stock price today?

Clearside Biomedical, Inc. (CLSD) is currently trading at $0.41, up 0% today.

What is CLSD P/E ratio?

Clearside Biomedical, Inc.'s P/E ratio is -0.11. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CLSD return on equity (ROE)?

Clearside Biomedical, Inc.'s return on equity (ROE) is 37.73%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Clearside Biomedical, Inc.'s market cap?

Clearside Biomedical, Inc. has a market capitalization of $2.15M.

NASDAQ · Biotechnology

Clearside Biomedical, Inc. (CLSD) Stock

$0.41 +0.00% NASDAQ: CLSD Healthcare

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space.

Valuation

Metric	Value
Price	$0.41
Market Cap	$2.15M
P/E Ratio	-0.11
P/B Ratio	-0.04
P/S Ratio	0.71
EPS (TTM)	$-7.05
52-Week High	$17.10
52-Week Low	$0.31
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	37.73%
ROA	-160.55%
ROCE	-178.25%
Gross Margin	89.02%
Operating Margin	-523.09%
Net Margin	-618.26%
Debt/Equity	-0.01
Current Ratio	2.98

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$8.0M	$30.0M	$1.0M	$8.0M	$2.0M
Operating Profit	$-18.0M	$-1.0M	$-30.0M	$-25.0M	$-29.0M
Net Profit	$-18.0M	$0	$-33.0M	$-32.0M	$-34.0M
EPS	$-5.85	$0.09	$-8.25	$-7.95	$-7.05
Op Margin	-227.2%	-2.1%	-2281.6%	-302.0%	-1735.7%

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$19.0M	$43.0M	$51.0M	$34.0M	$25.0M
Total Liabilities	$11.0M	$5.0M	$41.0M	$50.0M	$64.0M
Cash	$17.0M	$30.0M	$48.0M	$29.0M	$20.0M
Borrowings	$2.0M	$1.0M	$35.0M	$43.0M	$52.0M

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-13.0M	$-11.0M	$-13.0M	$-18.0M	$-25.0M
Investing Cash Flow	$0	$0	$0	$-4.0M	$-2.0M
Financing Cash Flow	$0	$0	$0	$-1.0M	$0
Net Cash Flow	$-5.0M	$13.0M	$18.0M	$-19.0M	$-9.0M
Free Cash Flow	$-13.0M	$-11.0M	$-14.0M	$-20.0M	$-26.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.43
FCF Yield	-747.41%
Quick Ratio	2.98
Interest Coverage	-1.98
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLR	$1.39	-0.71%	-1.91	$22.12M	0.00%
CASICASI Pharmaceuticals, Inc.	$0.15	+3.08%	-0.07	$2.33M	0.00%
CING	$4.52	-2.59%	-1.08	$25.34M	0.00%
ENTOEntero Therapeutics, Inc.	$2.85	-5.00%	-0.82	$13.58M	0.00%
KAPA	$0.30	-3.20%	-1.70	$6.42M	0.00%

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.

Clearside Biomedical, Inc. is headquartered in US.

Clearside Biomedical, Inc. (CLSD) stock trades at $0.41 with a market capitalization of $2.15M. The stock is valued at a price-to-earnings (P/E) ratio of -0.11, price-to-book of -0.04, price-to-sales of 0.71. Over the past 52 weeks the stock has ranged between $0.31 and $17.10, and currently trades 97.6% below its 52-week high.

On profitability, Clearside Biomedical, Inc. generates a return on equity (ROE) of 37.73% — well above the market average, a sign of a high-quality business, return on capital employed of -178.25%, an operating margin of -523.09%, a net profit margin of -618.26%.

Official website: www.clearsidebio.com